Doptelet (avatrombopag) is a prescription medication used to treat low platelet counts, a condition called thrombocytopenia. It works by stimulating the body’s own platelet production, mimicking a natural growth signal that tells bone marrow to make more platelets. The FDA has approved it for three specific situations, all involving patients whose platelet counts are dangerously low.
The Three Approved Uses
Doptelet is approved for adults with chronic liver disease who need a medical procedure but have platelet counts too low to safely undergo one. Procedures like biopsies or dental extractions carry bleeding risks, and patients with liver disease often can’t produce enough platelets on their own. Rather than receiving a platelet transfusion, these patients take Doptelet for a short course beforehand to boost their counts above 50,000 per microliter, the threshold generally considered safe for procedures.
The second use is for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system mistakenly destroys platelets. Doptelet is specifically reserved for people who haven’t responded well enough to at least one prior treatment, typically corticosteroids. It’s not a first-line option.
In July 2025, the FDA expanded approval to include children ages 1 and older with persistent or chronic ITP who also haven’t responded adequately to previous treatment. This made Doptelet one of the few platelet-boosting medications available for pediatric ITP patients.
How It Works in the Body
Platelets are made in bone marrow, and a protein called thrombopoietin (TPO) is the main signal telling the marrow to produce them. In people with liver disease, the liver can’t make enough TPO. In ITP, platelets get destroyed faster than they’re replaced. Either way, the count drops.
Doptelet binds to the same receptor that TPO uses, essentially faking the “make more platelets” signal. This triggers the bone marrow to ramp up production. Unlike a platelet transfusion, which provides a temporary supply of donated platelets, Doptelet prompts the body to build its own. The effect takes several days to kick in, which is why timing matters.
How Doptelet Is Taken
The medication comes as a 20 mg tablet and must be taken with food. How you take it depends entirely on the condition being treated.
For chronic liver disease patients preparing for a procedure, the course is short: five consecutive days of pills. The dose depends on your starting platelet count. If your count is below 40,000, you take 60 mg (three tablets) daily. If it falls between 40,000 and 50,000, the dose drops to 40 mg (two tablets) daily. Your procedure is then scheduled after the course is complete, once platelet counts have had time to rise.
For ITP, treatment is ongoing rather than a short burst. You start at 20 mg once daily, and your doctor adjusts the dose based on how your platelet counts respond. The goal is to keep counts at or above 50,000. The maximum daily dose is 40 mg. Because ITP is a chronic condition, this can mean taking Doptelet indefinitely, with regular blood draws to track your levels and fine-tune the dose.
Clinical Trial Results
Doptelet’s approval for liver disease came from two large trials called ADAPT-1 and ADAPT-2. Both compared Doptelet to a placebo in patients with chronic liver disease and low platelets who needed a procedure. Patients taking Doptelet were significantly more likely to reach the target platelet count of 50,000 on procedure day and significantly less likely to need a platelet transfusion or rescue therapy. In clinical trials for the liver disease indication, serious adverse reactions occurred in 7 to 8% of patients on Doptelet, which was comparable to (and in one group, lower than) the placebo rate.
Risks and Side Effects
The most important safety concern with Doptelet is the risk of blood clots. Because the drug boosts platelet production, it can sometimes push counts too high, increasing the chance of clots forming in blood vessels. This class of medication has been linked to portal vein thrombosis (a clot in the main vein supplying the liver) in patients with chronic liver disease. In the ADAPT trials, this occurred in 1 out of 430 patients treated with Doptelet.
The risk is higher for people who already have clotting tendencies, including inherited conditions like Factor V Leiden or deficiencies in natural anticlotting proteins. Your doctor will monitor your platelet counts throughout treatment and watch for signs of clotting complications. Doptelet has no listed contraindications, meaning there are no absolute reasons a person cannot take it, but the clotting risk requires careful monitoring.
Common, less serious side effects vary by condition. Liver disease patients most often report headache, fatigue, and fever. ITP patients may experience headache, fatigue, bruising, nosebleeds, and upper respiratory infections. Most of these are mild and overlap with symptoms of the underlying conditions themselves.
Who Doptelet Is Not For
Doptelet is not intended to normalize platelet counts in every person with low platelets. For ITP specifically, it’s positioned as a later-line treatment. You need to have tried and failed (or not tolerated) at least one prior therapy before it’s considered appropriate. Many treatment guidelines expect patients to have tried corticosteroids first, and some also require that second-line options like splenectomy or rituximab have been attempted or ruled out.
It’s also not designed for thrombocytopenia caused by chemotherapy, bone marrow failure syndromes, or other causes unrelated to liver disease or ITP. The drug was studied in specific populations, and its approval reflects those boundaries. For liver disease patients, it’s only indicated before a scheduled procedure, not as an ongoing treatment to keep platelet counts elevated.